Cargando…
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852980/ https://www.ncbi.nlm.nih.gov/pubmed/35150436 http://dx.doi.org/10.1007/s40265-022-01681-8 |
| _version_ | 1784653141687402496 |
|---|---|
| author | Lenze, Eric J. Reiersen, Angela M. Facente, Shelley N. |
| author_facet | Lenze, Eric J. Reiersen, Angela M. Facente, Shelley N. |
| author_sort | Lenze, Eric J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8852980 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88529802022-02-18 Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” Lenze, Eric J. Reiersen, Angela M. Facente, Shelley N. Drugs Letter to the Editor Springer International Publishing 2022-02-12 2022 /pmc/articles/PMC8852980/ /pubmed/35150436 http://dx.doi.org/10.1007/s40265-022-01681-8 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Lenze, Eric J. Reiersen, Angela M. Facente, Shelley N. Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title | Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title_full | Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title_fullStr | Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title_full_unstemmed | Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title_short | Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” |
| title_sort | authors’ reply to mazza et al.: “fluvoxamine for the early treatment of sars‑cov‑2 infection: a review of current evidence” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852980/ https://www.ncbi.nlm.nih.gov/pubmed/35150436 http://dx.doi.org/10.1007/s40265-022-01681-8 |
| work_keys_str_mv | AT lenzeericj authorsreplytomazzaetalfluvoxaminefortheearlytreatmentofsarscov2infectionareviewofcurrentevidence AT reiersenangelam authorsreplytomazzaetalfluvoxaminefortheearlytreatmentofsarscov2infectionareviewofcurrentevidence AT facenteshelleyn authorsreplytomazzaetalfluvoxaminefortheearlytreatmentofsarscov2infectionareviewofcurrentevidence |